Silicon Investor (SI) -- The First Internet Community

To: Jongmans who wrote (45)

10/17/2001 4:30:02 AM

From the rights announcement in March -

"...PPL has recently been awarded a contract by DARPA for up to $3.1 million to support research involving the potential to produce large quantities of human polyclonal antibodies against a range of biological warfare agents, such as Anthrax and Ebola (amongst others). PPL retains the rights to commercialise all non-military applications of the technology, for example, in the potential treatment of diseases such as autoimmune disease, hepatitis, HIV and cancer..."